Has Fred Rincon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $84,727 in general payments to Fred Rincon, MD across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fred Rincon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fred Rincon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fred Rincon, MD

Vascular Neurology · Camden, NJNPI 1326159443

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $62,510 of the $84,727 with a category attached, or 73.8%. 8 manufacturers reported payments, led by AstraZeneca at 47.0% of the total. Reporting peaked in 2019 at $33,349 and has fallen 77.0% since, to $7,661 in 2024.

$84,727in general payments, 2019–2025

Across 94 payments — averaging $901.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$40K
Portola Pharmaceuticals, LLC$26K
C. R. Bard, Inc. & Subsidiaries$9K
Medivance, Inc.$6K
Ceribell, Inc.$4K
Philips North America LLC$51
plus $63 from 2 others

What the payments were for

Consulting fees$11,51414%
Speaking & faculty fees$62,51074%
Travel & lodging$7,9179%
Food & beverage$2,7443%
Education$420%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	39	$39,807
Portola Pharmaceuticals, LLC	36	$25,629
C. R. Bard, Inc. & Subsidiaries	11	$9,174
Medivance, Inc.	2	$6,064
Ceribell, Inc.	1	$3,940
Philips North America LLC	3	$51
UCB, Inc.	1	$42
Chiesi USA, Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$53,803

Medicare patients

198

Services billed

371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Camden

Inder SinghNeptune$119K
Kevin CrutchfieldHackensack$19K
Peter BarcasNeptune$10K
Kiwon LeeSummit$7K
John HannaSummit$3K
Pratit PatelNeptune$3K
Laura RisleyNeptune$3K
Gerald FerenczToms River$2K
Steven ShapiroLivingston$2K
Paul KaiserLawrenceville$1K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →